Who is sponsoring NCT06173687?

NCT06173687 is sponsored by Cochlear.

What drugs are being tested in NCT06173687?

Interventions in NCT06173687: The impedance measurement task using the Mobile Research App (MRA).

What condition does NCT06173687 study?

NCT06173687 studies Hearing Loss.

Is NCT06173687 still recruiting?

NCT06173687 is currently completed. Last updated 3 December 2025.

Are results published for NCT06173687?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-12-03 · How we verify

NCT06173687: DICE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multi-center Study to Examine Changes to the Environment Surrounding the Electrodes in the Cochlea and to Capture the Most Challenging Listening Environments Experienced by Persons With a Cochlear Implant

Completed NA Results posted Last updated 3 December 2025

What this trial tests

NA trial testing The impedance measurement task using the Mobile Research App (MRA) in Hearing Loss in 51 participants. Completed in 24 October 2024.

Timeline

29 January 2024

Primary endpoint
24 October 2024

24 October 2024

Quick facts

Lead sponsor	Cochlear
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	51
Start date	29 January 2024
Primary completion	24 October 2024
Estimated completion	24 October 2024
Sites	4 locations across Belgium, Sweden, Australia

Drugs / interventions tested

The impedance measurement task using the Mobile Research App (MRA)

Conditions studied

Hearing Loss — all drugs for Hearing Loss →

Sponsor

Cochlear — full company profile →

Who can join

18 and older, any sex, with Hearing Loss. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Impedance Measurements Primary · 8 Weeks

Median of the standard deviation in total electrode impedance (measured in kOhm, averaged across 22 electrode contacts) between days for 8 weeks.

Group	Value	95% CI
All Participants	0.36	0.27 – 0.67

Adverse events — posted to ClinicalTrials.gov

Time frame: 8 weeks. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

All Participants

Serious: 3/51 (6%)

Deaths: 0/51

Serious adverse events (4 terms)

Reaction	System	All Participants
Tachycardia	Cardiac disorders	—
Epileptic seizures	Nervous system disorders	—
Myeloma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—
Breast cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—

Most-reported serious reactions: Tachycardia, Epileptic seizures, Myeloma, Breast cancer.

Data from ClinicalTrials.gov NCT06173687 adverse events section.

Sponsor's own description

This early feasibility study aims to collect pilot data on impedance measurements in real-world environments and to collect real-world and difficult listening situations and the factors impacting this, reflecting situations the subjects encounter during their daily life outside of the clinic. Improving the monitoring of both aspects may lead to improvements in monitoring and personalising the fitting to optimise hearing outcomes for persons with a cochlear implant.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hearing Loss

Currently open trials in the same condition.

NCT07176936 — Improving Speech in Noise Using Noninvasive Stimulation · NA · recruiting
NCT07506408 — Randomised Study of Web-Based Auditory Training With Varying Perceptual and Cognitive Demands on Training Gains and Gene · NA · recruiting
NCT07218913 — Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III · Phase 1 · recruiting
NCT07414329 — Efficacy and Effectiveness of an Investigational Behind-the-Ear Hearing Device Kit · NA · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Cochlear trials

Trials by the same sponsor.

NCT07077070 — Investigating Electrical Categorical Loudness Scaling Using a Mobile Research App in Experienced Adult Cochlear Implant · NA · completed
NCT07156461 — Hearing Outcomes With the Osia 3 Sound Processor Compared to the Osia 2 Sound Processor in Adult Osia Implant Recipients · NA · completed
NCT06338670 — Clinical Performance of the Osia 3 Sound Processor Compared With the Osia 2 Sound Processor in Adult Osia Implant Users · NA · completed
NCT06298396 — Investigating Stimulation Parameter and Electrode Mode Changes on Speech Perception in Experienced Adult Cochlear Implan · NA · completed
NCT06100393 — New Algorithms to Signal Processing for Speech Enhancement in Adult Cochlear Implant Recipients. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06173687 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cochlear
Last refreshed: 3 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06173687.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing